Showing results (131-140 of 141) with videos related to
Sort By:
Pageof 15
Clinical and Vaccine Immunology : CVI|September 26, 2014
Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participantsSharon E Frey, Laurence Peiperl, M Juliana McElrath, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|January 7, 2015
Impact of age on retention in care and viral suppressionBaligh R Yehia, Peter Rebeiro, Keri N Althoff, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|July 24, 2018
Brief Report: Reduced Use of Illicit Substances, Even Without Abstinence, Is Associated With Improved Depressive Symptoms Among People Living With HIVJoseph A Delaney, Robin M Nance, Bridget M Whitney, et al.The Lancet. HIV|October 6, 2023
Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trialMagdalena E Sobieszczyk, Sharon Mannheimer, Carmen A Paez, et al.AIDS Care|August 3, 2016
Not all non-drinkers with HIV are equal: demographic and clinical comparisons among current non-drinkers with and without a history of prior alcohol use disordersHeidi M Crane, Robin M Nance, Joseph O Merrill, et al.Pharmaceutics|May 25, 2024
Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIVBryan T Mayer, Lily Zhang, Allan C deCamp, et al.Antimicrobial Agents and Chemotherapy|March 30, 2023
Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083Mark A Marzinke, Jessica M Fogel, Zhe Wang, et al.The Journal of Infectious Diseases|October 5, 2023
Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120Zvavahera Mike Chirenje, Fatima Laher, One Dintwe, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|August 18, 2016
Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 TrialSusan H Eshleman, Sarah E Hudelson, Andrew D Redd, et al.The Lancet. HIV|December 12, 2024
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trialSrilatha Edupuganti, Christopher B Hurt, Kathryn E Stephenson, et al.Pageof 15